Prediction of CCND1 amplification using plasma DNA as a prognostic marker in oesophageal squamous cell carcinoma
Authors:
Open Access
- 13 April 2010
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 102 (9) , 1378-1383
Abstract
Background: Methods: Results: Conclusion:Keywords
This publication has 30 references indexed in Scilit:
- Cell-free Tumor DNA in Blood Plasma As a Marker for Circulating Tumor Cells in Prostate CancerClinical Cancer Research, 2009
- Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistryBMC Cancer, 2009
- Circulating mutant DNA to assess tumor dynamicsNature Medicine, 2008
- Genetic polymorphisms and esophageal cancer riskInternational Journal of Cancer, 2007
- Circulating nucleic acids (CNAs) and cancer—A surveyBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2007
- Detection of Epidermal Growth Factor Receptor Mutations in Serum as a Predictor of the Response to Gefitinib in Patients with Non–Small-Cell Lung CancerClinical Cancer Research, 2006
- Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylationBritish Journal of Cancer, 2006
- Comparison of methylation‐specific polymerase chain reaction (MSP) with reverse transcriptase‐polymerase chain reaction (RT‐PCR) in peripheral blood of gastric cancer patientsJournal of Surgical Oncology, 2004
- Quantification of Free Circulating DNA As a Diagnostic Marker in Lung CancerJournal of Clinical Oncology, 2003
- Amplification of the EGF receptor and c‐myc genes in human esophageal cancersInternational Journal of Cancer, 1988